AdipotideUnderstand the science
How to read adipotide’s terminated first-in-human trial
2 numbered sourcesSource years 2010–2019
Peptides are short amino-acid chains joined by peptide bonds. Their sequences can help researchers build molecules that recognize a specific protein or change how a cell behaves. Adipotide, studied under the name prohibitin targeting peptide 1, pairs a fat blood vessel recognition sequence with a cell-killing segment. Its older ClinicalTrials.gov record provides a concrete example of what a registered study can tell a reader when results are unavailable. [1, 2]
The M.D. Anderson Cancer Center study was registered as an early phase investigation in participants with both metastatic prostate cancer and obesity. The registry lists objectives concerning biological activity and tolerability. A measure of biological activity specified a change in weight or body mass index. An outcome description tells the reader what the investigators intended to measure. It gives no numerical result by itself. [1]
The record shows that four participants enrolled and that the study was terminated at the principal investigator’s request. The last posted update was in January 2019. The registry displays no posted results. That combination of facts leaves the size and direction of any human weight change unknown from the registry. It also leaves the participants’ individual safety outcomes and the detailed reason for stopping outside the public record. [1]
The primate study that preceded the clinical work offers the direct evidence for fat changes in monkeys and describes kidney effects there. Those data help explain why researchers wanted to study the compound in people, while the clinical record establishes only the existence, scope, and status of that attempt. Together, the two records illustrate the gap between a promising animal observation and a completed human test with outcomes that others can evaluate. [1, 2]
Sources
Original works cited in this article. Links open the external record in a new tab.
